Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation

Fatih Kaplan
Australasian Journal of Dermatology · Wiley · 2026-09-21 · DOI: 10.1111/ajd.70217

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles